Arcutis Biotherapeutics, Inc. (ARQT) Stock Overview
Explore Arcutis Biotherapeutics, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Arcutis Biotherapeutics, Inc. (ARQT)
Key Financials
Key Financials
Market Cap
3.3B
P/E Ratio
119.61
EPS (TTM)
$0.21
ROE
0.15%
ARQT Stock Analysis & Investment Overview (NASDAQ)
Our AI-powered analysis of Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B+, Arcutis Biotherapeutics, Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.
The current technical analysis of ARQT on the NASDAQ shows an RSI of 55.42, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $30.82 for the NASDAQ listing.
Key metrics behind Arcutis Biotherapeutics, Inc.'s NASDAQ-traded stock include a P/E ratio of 119.61 and a market capitalization of 3.3B. Combined with our AI analysis, these give both institutional and retail investors a clear view of ARQT on the NASDAQ.